Clinical Trials Logo
  1. Home
  2. Small Cell Lung Carcinoma
  3. NCT04620837

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma Clinical Trial

Official title:
A Prospective, Open Label, Single-arm, Phase 2 Study of Tislelizumab in Combination With Anlotinib as Maintenance Therapy in Subject With Extensive Stage Small Cell Lung Cancer （ES-SCLC） as Maintenance Therapy After First Line Chemotherapy

Clinical Trial Summary

To show that maintenance therapy with Tislelizumab plus Anlotinib will prolong Progression Free Survival in subjects with extensive stage disease small cell lung cancer who have completed first line chemotherapy.

Clinical Trial Description

Most patients with extensive disease small cell lung cancer (ED-SCLC) respond to first line（1L） platinum-based chemotherapy; however, responses are not durable and prognosis is poor. Currently no maintenance treatments are approved in SCLC to prolong the durability of efficacy achieved with 1L chemotherapy. Immuno-oncology agents have demonstrated efficacy in the treatment of ED-SCLC when administered across different lines of therapy. Tislelizumab (Anti-PD-1 antibody) Combine Etoposide+ platinum （EP） had improved median Overall survival （mOS ） to 15.6m of 1L ED-SCLC in the Rationale 206 study. Anlotinib ( RTKi ) had significantly improved PFS & OS of 3L(third line) ED-SCLC in the ALTER 1202. This phase II study is designed to explore the effect and safety of the combination as maintenance therapy for ED-SCLC after 1L chemotherapy ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04620837
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact Yuankai Shi, MD
Phone 86-10-87788293
Email syuankaipumc@126.com
Status Recruiting
Phase Phase 2
Start date November 1, 2020
Completion date December 31, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05882058 - DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers Phase 2
Terminated NCT03963414 - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC Phase 1
Active, not recruiting NCT04358237 - Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. Phase 1/Phase 2
Not yet recruiting NCT06419179 - Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) Phase 2
Completed NCT02874664 - A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer Phase 1
Completed NCT02397733 - Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL) N/A
Recruiting NCT01977235 - Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer Phase 2
Completed NCT00759824 - A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide Phase 2
Active, not recruiting NCT03568097 - Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer Phase 2
Withdrawn NCT02876081 - Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex Phase 2
Recruiting NCT06247605 - A Phase IIII Study of AL8326 in Small Cell Lung Cancer Phase 3
Recruiting NCT04996771 - Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT03662074 - Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer Phase 2
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Completed NCT01941316 - Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Phase 1/Phase 2
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Recruiting NCT06131840 - A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors Phase 1
Recruiting NCT05683977 - A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
Recruiting NCT05329623 - A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. Phase 1
Active, not recruiting NCT04902872 - Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors Phase 1/Phase 2